


Accepted Manuscript

Original article

HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe

Patrick Ingiliz, Thomas C Martin, Alison Rodger, Hans-Jürgen Stellbrink, Stefan Mauss, Christoph Boesecke, Mattias Mandorfer, Julie Bottero, Axel Baumgarten, Sanjay Bhagani, Karine Lacombe, Mark Nelson, Jürgen K Rockstroh, NEAT study group,



PII: S0168-8278(16)30505-0
DOI: <http://dx.doi.org/10.1016/j.jhep.2016.09.004>
Reference: JHEPAT 6259

To appear in: *Journal of Hepatology*

Received Date: 30 November 2015
Revised Date: 30 August 2016
Accepted Date: 7 September 2016

Please cite this article as: Ingiliz, P., Martin, T.C., Rodger, A., Stellbrink, H-J., Mauss, S., Boesecke, C., Mandorfer, M., Bottero, J., Baumgarten, A., Bhagani, S., Lacombe, K., Nelson, M., Rockstroh, J.K., NEAT study group, HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe, *Journal of Hepatology* (2016), doi: <http://dx.doi.org/10.1016/j.jhep.2016.09.004>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Original Article

**HCV reinfection incidence and spontaneous clearance rates in HIV-
positive men who have sex with men in Western Europe**

Patrick Ingiliz*¹, Thomas C Martin*², Alison Rodger³, Hans-Jürgen Stellbrink⁴,
Stefan Mauss⁵, Christoph Boesecke⁶, Mattias Mandorfer⁷, Julie Bottero⁸, Axel
Baumgarten¹, Sanjay Bhagani³, Karine Lacombe^{8,9}, Mark Nelson^{2,10}, Jürgen K
Rockstroh⁶, NEAT study group

* contributed equally

¹Center for Infectiology (CIB), Berlin, Germany, ²Chelsea and Westminster Hospital, London,
United Kingdom, ³The Royal Free Hospital, London, United Kingdom, ⁴Infectiology Center
Hamburg (ICH), Hamburg, Germany, ⁵Center for HIV and Hepatogastroenterology,
Duesseldorf, Germany, ⁶University of Bonn, Department of Medicine I, Bonn, Germany,
⁷Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical
University of Vienna, Vienna, Austria, ⁸Service des maladies infectieuses et tropicales, Hôpital
Saint-Antoine, AP-HP, ⁹Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre
Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France, ¹⁰Imperial
College School of Medicine, London, United Kingdom

Corresponding author: Patrick Ingiliz, MD, Center for Infectiology (CIB), Seestr.
13, 13353 Berlin, Tel: +49-30-451988940, Fax: +49-30-4519889424,
ingiliz@zibp.de

Word count (abstract): 250

Word count (manuscript including references, abstract, and legends): 4705

Tables: 2

Figures: 2

Abbreviations

HIV – human immunodeficiency virus

ART – antiretroviral therapy

HCV – hepatitis C virus

PWID – people who inject drugs

MSM – men who have sex with men

PR – pegylated interferon and ribavirin

DAA – direct acting antiviral agent

SVR – sustained virological response

py – person-years

NEAT – European AIDS Treatment Network

ALT – alanine aminotransferase

CD – cluster of differentiation

IQR – interquartile range

CI – confidence interval

OR – odds ratio

Keywords: HCV reinfection, acute hepatitis C, HIV-HCV coinfection, SVR, spontaneous clearance, HCV therapy

The authors declare no conflict of interest with regards to the manuscript.

No financial support was obtained for this article.

Authors contribution: PI, TCM, MN, and JKR designed the study. PI and TCM drafted the manuscript. TCM performed the data analysis. AR, HJS, SM, CB, MM, JB, AB, SB, KL included patients. All authors discussed and approved the final manuscript.

ACCEPTED MANUSCRIPT

Abstract:

Background and Aims: Moderate cure rates of acute hepatitis C virus (HCV) infections with pegylated interferon and ribavirin (PR) have been described in the last decade in men who have sex with men (MSM) who are coinfecting with the human immunodeficiency virus (HIV). However, a subsequent high incidence of HCV reinfections has been reported regionally in men who both clear the infection spontaneously or who respond to treatment.

Methods: Retrospective analysis of reinfections in HIV infected MSM in eight centers from Austria, France, Germany, and the UK within the NEAT network between May 2002 and June 2014.

Results: Of 606 individuals who cleared HCV spontaneously or were successfully treated, 149 (24.6%) presented with a subsequent HCV reinfection. 30 out of 70 (43%) who cleared again or were successfully treated, presented with a second reinfection, 5 with a third, and one with a fourth reinfection. The reinfection incidence was 7.3/100 person-years (95% CI 6.2-8.6). A trend for lower incidence among individuals who had spontaneously cleared their incident infection than among individuals who were treated was found (Hazard ratio 0.62, 95% CI 0.38-1.02, $p=0.06$). Spontaneous clearance of reinfection was associated with ALT levels >1000 IU/ml and spontaneous clearance of a prior infection.

Conclusions: HCV reinfection is an issue of major concern in HIV-positive MSM. Prevention strategies are needed for high-risk groups to reduce morbidity and treatment costs. HIV-positive MSM with a prior

HCV-infection should be tested every 3 to 6 months for reinfection, those who had achieved a reinfection every 3 months.

Keywords: HCV reinfection, acute hepatitis C, HIV-HCV coinfection, SVR, spontaneous clearance, HCV therapy

Lay summary: We evaluated the occurrence of HCV reinfection in HIV-positive men who have sex with men who were cured for a previous HCV infection. We found an alarming incidence of 7.3/100 person-years. Prevention measures need to address this specific subgroup of patients at high risk for HCV.

ACCEPTED MANUSCRIPT

Introduction

Liver disease represents a major cause of morbidity and mortality among patients infected with the human immunodeficiency virus (HIV) in the developed world(1). In the setting of effective combined antiretroviral therapy (cART) and the successful preservation of a patient's immune function, chronic infection with hepatitis C virus (HCV) is currently the main cause for liver related mortality due to liver failure and hepatocellular carcinoma(2, 3).

In recent years, HCV seroconversions within European HIV cohorts have been reported among people who inject drugs (PWID) and men who have sex with men (MSM)(4, 5). In the case of the MSM community, several outbreaks of acute HCV infection have been described in Western metropolitan areas over the last decade associated with high-risk sexual practices, genital ulcer disease and recreational drug use including parenteral administration(6-8). Treatment uptake with interferon-based therapy has generally been high in the HIV-positive MSM population and high SVR rates have been reported as many, if not most, are treated in the acute infection phase(9). Yet despite these outcomes the epidemic has continued unabated (5, 10).

Several new direct-acting antivirals (DAAs) have been approved for interferon-free treatment of chronic HCV in Europe. Most of these agents are characterized by a favorable interaction profile with antiretroviral medication and sustained virological response (SVR) rates above 90% in clinical trials in the HIV/HCV coinfecting population(11-14). Mathematical modeling predicts substantial reductions in HCV prevalence in HIV infected MSM within a decade(15) (16)if the required scale-up in treatment uptake with these new compounds is achieved. Further benefits have been predicted if treatment is combined with an intervention to reduce behavioral risk, which makes the eradication of HCV an achievable goal in the HIV-HCV coinfecting population in Western Europe.

In the presence of maintained risk behavior, HCV reinfections have been described in PWID and MSM who either cleared their initial infection spontaneously or were successfully treated with interferon-based therapies(17-20). In a recent meta-analysis of 61 studies, the five-year risk of HCV reinfection in HIV infected MSM was as high as 15% and higher than in studies on PWID(21). Two studies to date have described reinfection incidence among HIV-HCV coinfecting MSM with reported rates of 8-15 per 100 person-years (py)(19, 22). More recently, HCV reinfections have also been reported in phase 3 trials of DAA HCV compounds(12, 14, 23) nearly all of which have occurred among HIV infected MSM.

Data from London reported that individuals who spontaneously clear their acute infection may be at lower risk of future HCV reinfection

when compared to those who are treated and achieve SVR. This indicates that a degree of protective immunity may develop for some patients(19). An effective immune response against HCV through multiple infections has been shown in animal models(24); however, studies among PWID have failed to consistently demonstrate a protective effect(18, 25).

An accurate description of the HCV epidemic including a concise observation of reinfections in specific populations will be crucial to achieve the goal of HCV eradication and to reduce costs of repeated DAA treatment. This study quantifies the rate of HCV reinfections among HIV infected MSM from seven urban European areas and investigates potential variables associated with repeat spontaneous viral clearance.

Methods

The dataset for this analysis was merged from eight centers in four countries within the NEAT (European AIDS Treatment Network) consortium: The Chelsea and Westminster Hospital and the Royal Free Hospitals, London, the St. Antoine Hospital, Paris, the Center for Infectiology, Berlin, the Center for Infectious Medicine Hamburg, the Center for HIV and Hepatogastroenterology, Duesseldorf, the University Hospital Bonn, and the Medical University of Vienna.

In all centers, the available data have been homogenized due to previous collaborations such as the NEAT Probe-C cohort.

All HIV-positive MSM from these centers with a history of a cured first HCV infection were identified with subsequent HCV PCR results

followed through time to detect reinfection.

HCV cure was defined as follows:

- Patients with SVR defined by a negative HCV PCR at least 12 weeks after the end of an interferon-based treatment and at least 1 subsequent HCV PCR measurement.
- Patients with a spontaneously cleared HCV infection, defined by at least two negative HCV PCR measurements at least 24 weeks apart following HCV infection.

The following data were collected for all patients: Age, date of diagnosis of acute HCV infection, HCV genotype, date of HCV cure, whether cure was a result of treatment or spontaneous clearance, and date of last follow-up visit.

HCV RNA measurements were not standardized and depended on local operating procedures which ranged between once per year and every three months and in the case of newly developed ALT elevation.

Reinfection was defined as a detectable HCV RNA at any timepoint after cure, or within the above mentioned time frames, if a HCV genotype/subtype switch occurred. In men who had a reinfection episode, the following data was obtained at the first HCV infection and at each new infection episode: age, duration of HIV infection, date of first HCV infection, HCV genotype, HCV viral load at diagnosis, maximum alanine aminotransferase (ALT), CD4 cell count, HIV viral load, HIV treatment status. Date of HCV cure, whether cure was as a result of treatment or

spontaneous clearance and date of last follow-up visit were further collected.

In patients who achieved multiple SVRs or spontaneous clearances, the time-point of subsequent reinfections and the described variables were documented.

Reinfection incidence was calculated using Kaplan-Meier survival time methods. The start of follow up was defined as the date of end of HCV treatment for individuals who were successfully treated and as the first negative HCV-RNA PCR for individuals who spontaneously cleared their infection. For individuals that underwent reinfection, the date of failure was taken as the date of newly positive HCV RNA PCR. Individuals who did not undergo reinfection were censored at the date of last negative HCV PCR available. Comparison of reinfection incidences were calculated using logrank test and cox proportional hazards model. Variables associated with spontaneous clearance of reinfection were evaluated using logistic regression. Continuous variables were grouped (Age: ≤ 30 , ALT ≤ 1000 IU/ml at initial infection and reinfection, HCV VL of 1st infection ≤ 500000 copies/ml, HIV VL undetectable at 1st infection, CD4 at first infection by brackets of 100 cells/ml, CD4 at reinfection by brackets of 100 cells/ml). All variables that had an association with a p-value < 0.1 were further explored for association using multiple logistic regression. Only age and initial infection outcomes were available for regression with reinfection as the outcome. McNemar's test was used to compare the spontaneous clearance proportions for the 1st and 2nd reinfections. All analyses were

performed using Stata version 12.0.

Results

606 HIV-positive MSM with a documented cure of HCV infection between May 2002 and February 2014 were identified. SVR following treatment with pegylated interferon +/- ribavirin was achieved in 494 (81.5%) men, while 111 (18.3%) exhibited spontaneous viral clearance, and in one patient the type of cure was not documented.

During follow up until June 2014, 149 of these men (24.6%) presented with a de-novo acute HCV reinfection episode. In 95% (135/142) of cases, an ALT elevation above 41 IU/mL was observed.

The median CD4 cell count at reinfection was 533/mm³ (IQR 412-760) and 82% of reinfected patients had an HIV viral load less than 50 copies/ml at time of reinfection. The median duration of diagnosed HIV infection at HCV reinfection was 9 years (IQR 6-14). 70 patients had a documented cure or spontaneous clearance of their first reinfection of which 30 (43%) presented with a second reinfection a median of 1.8 years (IQR 1.2-2.4) after clearance of their prior infection. Five patients had a third reinfection, and in one patient a fourth reinfection occurred. Table 1 shows details of primary and reinfection genotypes, ages, SVR proportions and spontaneous clearance proportions.

Reinfection incidence

In calculating reinfection incidence, 54 patients from 3 centers were excluded due to incomplete datasets (no date for end of follow up, no

date for start of follow up, incorrectly entered end of follow up date). 552 patients were therefore included in the analysis representing 1952 person-years (py) of follow-up with a median follow up time of 3.0 years (IQR 1.6-4.9, min 0.02/max 11.4 years).

The overall median follow-up time was 3.0 years (interquartile range (IQR) 1.6-4.9 years).

In total, 143 HCV reinfections occurred at a rate of 7.3/100 person-years (95% confidence interval (CI) 6.2-8.6). The median duration to reinfection was 2.0 years (IQR 1.1-3.3 years). There was a trend for higher reinfection incidence among individuals who achieved SVR following treatment for their incident infection (7.8/100 py) compared to reinfection incidence among individuals who had spontaneously cleared their incident infection (4.9/100 person-years; crude unadjusted hazard ratio for reinfection 0.62, 95%-CI 0.32-0.95, $P = 0.06$). Figure 1 is the Kaplan-Meier curve showing survival from reinfection for all patients with 95% confidence intervals.

Sixty-four men either spontaneously cleared or were successfully treated for their subsequent HCV reinfection and had follow up data available representing 143 py of follow up (Median follow up 1.8 years IQR 0.9-2.8). Of these 64 men, 27 presented with a second reinfection at a median of 1.7 years (IQR 1.2-2.4) after cure of the prior infection. The second reinfection incidence rate was significantly higher than the first reinfection incidence at 18.8/100py (95% CI 12.9-27.5; hazard ratio for second reinfection 2.51, 95% CI 1.7-3.8, $p < 0.001$).

Table 2 depicts the reinfection incidence per center, with the highest

being in Paris (21.8/100py, 95% CI 11.3-41.8), followed by Vienna (16.8/100py, 95%CI 8.7-32.3), Berlin (8.2/100py, 95% CI 5.6-12.1), Duesseldorf (8.1/100py, 95% CI 4.6-14.3), and London/Chelsea Westminster (7.0/100py, 95% CI 5.3-9.1). The lowest in incidence rate was seen in Hamburg (5.0/100py, 95% CI 2.9-8.7). The incidence rate decreased only slightly over time (Figure 2).

Spontaneous clearance rates

Twenty-one of 135 patients (15.6%) spontaneously cleared their first reinfection and 7 of 22 patients (28.6%) spontaneously cleared their 2nd reinfection ($p=0.43$ for increase in spontaneous clearance proportion).

Men who spontaneously cleared their incident infection were less likely to present with a subsequent reinfection episode than men who had achieved SVR to their incident infection (OR 0.52, 95% CI 0.29-0.91, $p=0.02$). In multivariable analysis, spontaneous clearance of the first HCV infection (OR=7.47, 95%CI 1.9-29.2, $p=0.004$) and a maximum ALT level above 1000 IU/mL (OR=13.9, 95%CI 4.3-45.4, $p<0.001$) were associated with spontaneous clearance of the reinfection(26).

Discussion

This is the largest cohort of HIV infected MSM patients followed-up longitudinally for HCV reinfections after initial HCV cure. We found a high reinfection incidence of 7.3/100py with an estimate that almost one third of patients being reinfected after 5 years. These numbers highlight the failure of current prevention strategies and the need for

specific measures in the HIV-infected MSM population at risk in Europe. With a high treatment uptake in this population even in the interferon era and with higher response rates to treatment in the acute phase of infection(27), reinfections are occurring most likely due to maintained risk behaviors. As new, well tolerated, but costly HCV treatments have become the standard of care for HCV therapy, there is an urgent need to develop strategies to prevent reinfection at such scale. It is essential to expand testing opportunities to identify at the earliest opportunity men in the early stages of infection to prevent onward transmission of infection through treatment and behavioral interventions. The men included in this study were all linked to care where if retained in care they are closely monitored and frequently tested for HCV reinfection using HCV RNA. Rapid access to effective treatment in conjunction with interventions to reduce high risk behaviours are then required.

The mode of transmission is not entirely understood in this population, but seems to occur in the setting of HIV infection, potential traumatic sexual practices with increased risk of blood-blood contact, and increasing recreational drug use including intravenous administration, commonly referred to as “Chemsex”(28). “Chemsex” is defined as the use of sexually disinhibiting recreational drugs to facilitate sexual sessions lasting often several days with multiple sexual partners and which put men at high risk of infection with HCV and other STIs(29). Our patients had a median age of 41 years at their first reinfection and well-controlled HIV infection, indicating that they were aware and compliant to health interventions, but potentially also driving their

willingness for unprotected and/or chemically enhanced sex. The dramatic incidence rate observed here confirms on a European level what has previously been reported (19, 20, 22) on a regional level.

Studies in PWID, all much smaller than the number of included individuals in this study, have shown HCV reinfection incidence rates between 0.8 and 4.7 per 100 person-years(30). In a meta-analysis performed by Aspinall et al. the pooled reinfection incidence in those reporting intravenous drug use after HCV cure was 6.44 (95% CI, 2.49-16.69) per 100 py(31). Hill et al. reported a five-year risk for HCV reinfection of 10.6% in PWID whilst it was over 15% in MSM(21). These findings underline the need for risk-adapted interventions during follow-up post HCV cure. HIV-positive MSM with a history of HCV infection and especially those presenting with an HCV reinfection require close monitoring and behavioral interventions to reduce the risk of reinfection.

We observed large regional differences in reinfection incidence within our dataset, with the highest being in Paris (21.8/100 patient-years) and the lowest being in Hamburg (5.04/100 patient-years). These differences may reflect the lack of precision in the incidence estimates from the smaller centers due to lower numbers of men included in the dataset and the shortest follow-up time or it may represent specific risk behavior patterns in men seen in the different centers, rather than absolute differences in incidences in the regions.

The reinfection incidence rates increased from the first reinfection (7.3/100py, 95% CI 6.2-8.6) to the second reinfection (18.8/100py,

95% CI 12.9-27.5, $p < 0.001$). This indicates a maintained risk behavior in a potentially specific high-risk group, who require urgent targeting for prevention measures related to risk behaviors. How often these individuals require testing for HCV infection de novo is unclear but the present suggestion that this occurs annually does not appear sufficient, and we suggest HCV RNA testing every three to six months after an incident HCV infection and every three months in patients that had been reinfected.

We found a spontaneous HCV clearance rate of 15.6% at the first reinfection episode consistent with findings from others in HIV-HCV-coinfected populations(26). However, at second reinfection the spontaneous clearance rate showed a non-significant increase to 28.6%. Individuals who had spontaneously cleared their initial infection were more likely to spontaneously clear ($p = 0.004$) their reinfection, and there was also a trend for lower reinfection incidence for people who had spontaneously cleared their initial infection compared to those that were treated (HR 0.62, 95% CI 0.38-1.02, $p = 0.06$). These findings would suggest the development of a degree of HCV-specific immunity with repeated exposure, which has been previously demonstrated in humans and chimpanzees(24, 25). The absence of this observation in the setting of in PWID may be explained by the type or frequency of HCV exposure, or the testing interval(32).

Several mechanisms of the host's immune response have been associated with spontaneous HCV clearance, including interferon-mediated natural killer (NK) cell response(33), a broad multispecific

CD4 T cell response(34), neutralizing antibodies(35), and the presence of specific HLA epitopes(36).

The ability to clear an acute HCV infection spontaneously is reduced in HIV-infected patients probably due to a compromised immune response. Factors such as female sex(37), coinfection with hepatitis B virus, a favorable IL28B genotype(38), and a higher CD4 cell count have been associated with clearance in clinical cohorts, as well as higher ALT levels, higher bilirubin levels, a faster decline in HCV viral load(26), and a less diverse viral quasispecies(39). Likewise, in this study, ALT levels above 1000 IU/mL were associated with spontaneous clearance as it has been described by other groups(26). These observations potentially reflect a stronger and more directed immune response against HCV in those who clear spontaneously. It remains however unclear why we observed spontaneous clearance in those with their first reinfection that did not clear the succeeding infection.

This study has a number of limitations. First of all, the retrospective nature of the study limits the conclusions that may be drawn from the analysis. In addition, detailed patient information was only available for men that acquired reinfection, limiting the analysis of risk. We may have underestimated the number of reinfections as those that cleared their infection within testing intervals may have been missed. On the other hand, false positive HCV RNA assay may have led to overestimation of cases. The HCV-RNA PCR testing interval was not standardized across centers and depended largely on the treating physician or national guidelines. But we believe that reasonable HCV-

RNA PCR testing would have been performed as all our patients were HIV-seropositive MSM with a high grade of linkage-to-care and regular medical visits at experienced STD centers/HIV outpatient clinics, usually every three months. Some datasets were incomplete leading to exclusion from detailed analysis. In addition, the majority of centers did not routinely test for IL28B genotype substantially limiting the analysis of this factor for risk of reinfection and spontaneous clearance.

Our study lacks detailed behavioral information, notably on injection drug use in this population, which hampers conclusions on prevention efforts.

Phylogenetic analysis was not performed in our cohort, and nearly half were reinfected with the same HCV subtype. Others have described a prolonged fluctuating viraemia that may be confounded with a new HCV infection(18). However, our patients were nearly exclusively diagnosed as acute HCV infection and the median ALT levels at reinfection were 302 and 268 IU/ml at the first and second reinfection, which makes chronic infection less likely. As we included treated patients and did not perform next-generation sequencing, we can not rule out the re-emergence of a resistant minority variant as has been previously postulated(40). However, the high treatment response rates and high spontaneous clearance rates in our patients' succeeding episodes make this hypothesis unlikely.

Conclusions

HCV reinfection is a critical health concern among HIV infected MSM

and frequently occurs after successful treatment or spontaneous clearance of acute HCV infection. Prevention strategies – both treatment and behavioral – are needed to target high-risk groups to reduce morbidity and treatment costs. Patients as well as clinicians have to be aware of the specific risk-behavior in this setting and counseling should be accompanied by behavioral interventions to avoid reinfections.

HIV-positive MSM with a prior HCV-infection should be regularly tested for reinfection. The increase in spontaneous clearance rates observed in our cohort indicates a possible increase of HCV-specific responses with repeated infection.

Acknowledgements: NEAT is a project funded by the European Union under the 6th Framework programme, contract acronym: NEAT, number: LSHP-CT-2006-037570.

1. Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. *Lancet*. 2014;384(9939):241-8.
2. Ioannou GN, Bryson CL, Weiss NS, Miller R, Scott JD, Boyko EJ. The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection. *Hepatology*. 2013;57(1):249-57.
3. Rosenthal E, Roussillon C, Salmon-Ceron D, Georget A, Henard S, Huleux T, et al. Liver-related deaths in HIV-infected patients between 1995 and 2010 in France: the Mortavic 2010 study in collaboration with the Agence Nationale

- de Recherche sur le SIDA (ANRS) EN 20 Mortalite 2010 survey. *HIV medicine*. 2015;16(4):230-9.
4. Boesecke C, Grint D, Soriano V, Lundgren JD, d'Arminio Monforte A, Mitsura VM, et al. Hepatitis C seroconversions in HIV infection across Europe: which regions and patient groups are affected? *Liver international : official journal of the International Association for the Study of the Liver*. 2015.
 5. **Wandeler G, Schlauri M, Jaquier ME**, Rohrbach J, Metzner KJ, Fehr J, et al. Incident Hepatitis C Virus Infections in the Swiss HIV Cohort Study: Changes in Treatment Uptake and Outcomes Between 1991 and 2013. *Open forum infectious diseases*. 2015;2(1):ofv026.
 6. Danta M, Brown D, Bhagani S, Pybus OG, Sabin CA, Nelson M, et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. *Aids*. 2007;21(8):983-91.
 7. van de Laar TJ, Matthews GV, Prins M, Danta M. Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. *Aids*. 2010;24(12):1799-812.
 8. Urbanus AT, van de Laar TJ, Stolte IG, Schinkel J, Heijman T, Coutinho RA, et al. Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic. *Aids*. 2009;23(12):F1-7.
 9. Boesecke C, Rockstroh JK. Treatment of acute hepatitis C infection in HIV-infected patients. *Current opinion in HIV and AIDS*. 2011;6(4):278-84.
 10. Urbanus AT, Van De Laar TJ, Geskus R, Vanhommerig JW, Van Rooijen MS, Schinkel J, et al. Trends in hepatitis C virus infections among MSM attending a sexually transmitted infection clinic; 1995-2010. *Aids*. 2014;28(5):781-90.
 11. Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, et al. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. *The New England journal of medicine*. 2015.
 12. Sulkowski MS, Eron JJ, Wyles D, Trinh R, Lalezari J, Wang C, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. *Jama*. 2015;313(12):1223-31.
 13. Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, et al. Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. *The New England journal of medicine*. 2015.
 14. Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. *The lancet HIV*. 2015;2(8):e319-27.
 15. Martin NK, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, Lima VD, et al. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. *Hepatology*. 2013;58(5):1598-609.
 16. **Martin NK, Thornton A**, Hickman M, Sabin C, Nelson M, Cooke GS, et al. Can Hepatitis C Virus (HCV) Direct-Acting Antiviral Treatment as Prevention Reverse the HCV Epidemic Among Men Who Have Sex With Men in the United Kingdom? *Epidemiological and Modeling Insights*. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2016;62(9):1072-80.

17. Grebely J, Prins M, Hellard M, Cox AL, Osburn WO, Lauer G, et al. Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. *The Lancet Infectious diseases*. 2012;12(5):408-14.
18. Sacks-Davis R, Grebely J, Dore GJ, Osburn W, Cox AL, Rice TM, et al. Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection-the InC3 Study. *The Journal of infectious diseases*. 2015.
19. Martin TC, Martin NK, Hickman M, Vickerman P, Page EE, Everett R, et al. Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM. *Aids*. 2013;27(16):2551-7.
20. Ingiliz P, Krznanic I, Stellbrink HJ, Knecht G, Lutz T, Noah C, et al. Multiple hepatitis C virus (HCV) reinfections in HIV-positive men who have sex with men: no influence of HCV genotype switch or interleukin-28B genotype on spontaneous clearance. *HIV medicine*. 2014;15(6):355-61.
21. Simmons B, Saleem J, Hill A, Riley RD, Cooke GS. Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2016;62(6):683-94.
22. Lambers FA, Prins M, Thomas X, Molenkamp R, Kwa D, Brinkman K, et al. Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM. *Aids*. 2011;25(17):F21-7.
23. Sarrazin C, Isakov V, Svarovskaia E, Martin R, Chodavarapu K, Hedskog C, Brainard D, Miller M, Mo H, Molina JM, Sulkowski MS, editor HCV Reinfection in Phase 3 Studies of Sofosbuvir 50th Annual Meeting of the European Association for the Study of the Liver; April 22-26, 2014; Vienna, Austria Abstract P0063.
24. Lanford RE, Guerra B, Chavez D, Bigger C, Brasky KM, Wang XH, et al. Cross-genotype immunity to hepatitis C virus. *Journal of virology*. 2004;78(3):1575-81.
25. Osburn WO, Fisher BE, Dowd KA, Urban G, Liu L, Ray SC, et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. *Gastroenterology*. 2010;138(1):315-24.
26. Thomson EC, Fleming VM, Main J, Klenerman P, Weber J, Eliahoo J, et al. Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men. *Gut*. 2011;60(6):837-45.
27. Boesecke C, Ingiliz P, Reiberger T, Stellbrink HJ, Bhagani S, Page E, et al. Dual treatment of acute HCV infection in HIV co-infection: influence of HCV genotype upon treatment outcome. *Infection*. 2015.
28. Bourne A, Reid D, Hickson F, Torres-Rueda S, Weatherburn P. Illicit drug use in sexual settings ('chemsex') and HIV/STI transmission risk behaviour among gay men in South London: findings from a qualitative study. *Sexually transmitted infections*. 2015.
29. Daskalopoulou M, Rodger A, Phillips AN, Sherr L, Speakman A, Collins S, et al. Recreational drug use, polydrug use, and sexual behaviour in HIV-diagnosed men who have sex with men in the UK: results from the cross-sectional ASTRA study. *The lancet HIV*. 2014;1(1):e22-31.
30. Grady BP, Schinkel J, Thomas XV, Dalgard O. Hepatitis C virus reinfection following treatment among people who use drugs. *Clinical*

infectious diseases : an official publication of the Infectious Diseases Society of America. 2013;57 Suppl 2:S105-10.

31. Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ, et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2013;57 Suppl 2:S80-9.
32. Vickerman P, Grebely J, Dore GJ, Sacks-Davis R, Page K, Thomas DL, et al. The more you look, the more you find: effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study design. *The Journal of infectious diseases*. 2012;205(9):1342-50.
33. Kokordelis P, Kramer B, Korner C, Boesecke C, Voigt E, Ingiliz P, et al. An effective interferon-gamma-mediated inhibition of hepatitis C virus replication by natural killer cells is associated with spontaneous clearance of acute hepatitis C in human immunodeficiency virus-positive patients. *Hepatology*. 2014;59(3):814-27.
34. **Schulze Zur Wiesch J, Ciuffreda D**, Lewis-Ximenez L, Kasprovicz V, Nolan BE, Streeck H, et al. Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence. *The Journal of experimental medicine*. 2012;209(1):61-75.
35. **Pestka JM, Zeisel MB**, Blaser E, Schurmann P, Bartosch B, Cosset FL, et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. *Proceedings of the National Academy of Sciences of the United States of America*. 2007;104(14):6025-30.
36. Kim AY, Kuntzen T, Timm J, Nolan BE, Baca MA, Reyor LL, et al. Spontaneous control of HCV is associated with expression of HLA-B 57 and preservation of targeted epitopes. *Gastroenterology*. 2011;140(2):686-96 e1.
37. Page K, Hahn JA, Evans J, Shiboski S, Lum P, Delwart E, et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. *The Journal of infectious diseases*. 2009;200(8):1216-26.
38. Tillmann HL, Thompson AJ, Patel K, Wiese M, Tenckhoff H, Nischalke HD, et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. *Gastroenterology*. 2010;139(5):1586-92, 92 e1.
39. Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. *Science*. 2000;288(5464):339-44.
40. Abdelrahman T, Hughes J, Main J, McLauchlan J, Thursz M, Thomson E. Next-generation sequencing sheds light on the natural history of hepatitis C infection in patients who fail treatment. *Hepatology*. 2015;61(1):88-97.

Authors names in bold designate shared co-first authorship.

Figure 1: Kaplan Meier showing estimates for the proportion of HIV positive MSM surviving free from HCV reinfection following spontaneous clearance or treatment of an initial HCV infection over time

Figure 2: HCV reinfection incidence in Western Europe over time.


ACCEPTED MANUSCRIPT

Table 1: Baseline characteristics at incident infection and reinfection


	Incident Infection	1 st Reinfection	2 nd Reinfection
Number included	N/A	606	70
Number of reinfections (%)	606	149 (24.6)	30 (42.9)
Genotypes	GT1 376(70.5) GT2 13(2.4) GT3 46(8.6) GT4 96 (18) Mixed GT1,3 – 2(0.4)	GT1 104(73.2) GT2 1(0.7) GT3 12(8.5) GT4 25(17.6)	GT1 23(85.2) GT2 0 GT3 1(3.7) GT4 3(11.1)
Proportion with genotype switches	N/A	71/136 (52)	14/26 (54)
Median age (IQR)	39 (34-44)	41 (37-45)	42 (40-48)
Proportion that clear spontaneously (%)	N/A	21/135 (15.6%)	7/22 (28.6%)
SVR proportion (%)	N/A	76/108 (70)	12/13 (92)

Table 2: HCV reinfection incidence among HIV positive MSM by location in Western Europe

Centre	Incidence reinfections/100py (95% CI)	Number of reinfections	Person years follow up
Duesseldorf (n=59)	8.1 (4.6-14.3)	12	148
Hamburg (n=73)	5.0 (2.9-8.7)	13	258
Berlin (n=95)	8.2 (5.6-12.1)	26	316
Bonn (n=11)	4.8 (0.7-33.7)	1	21
London – Chelwest (n=190)	7.0 (5.3-9.1)	52	746
London – Royal Free (n=69)	5.7 (3.7-8.7)	21	369
Paris (n=27)	21.8 (11.3-41.8)	9	41
Vienna (n=28)	16.8 (8.7-32.3)	9	54



HCV reinfection incidence in Western Europe over time



Time period	Person years follow up	Number of reinfections	Reinfection incidence, per 100py (95% CIs)
2002-2006	151	13	8.6 (5.0-14.8)
2006-2010	666	54	8.1 (6.2-10.6)
2010-2014	1119	76	6.8 (5.4-8.5)

Centre	Incidence reinfections/100py (95% CI)	Number of reinfections	Person-years follow up
Duesseldorf (n=59)	8.1 (4.6-14.3)	12	148
Hamburg (n=73)	5.0 (2.9-8.7)	13	258
Berlin (n=95)	8.2 (5.6-12.1)	26	316
Bonn (n=11)	4.8 (0.7-33.7)	1	21
London – Chelsea (n=190)	7.0 (5.3-9.1)	52	748
London – Royal Free (n=69)	5.7 (3.7-8.7)	21	369
Paris (n=27)	21.8 (11.3-41.8)	9	41
Vienna (n=28)	16.8 (8.7-32.3)	9	54

